A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Pneumonia Clinical Trial

Official title:

A Randomized, Double-blind, Parallel-Controlled Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02494999
• Other study ID #: JSVCT022
• Status: Completed
• Phase: Phase 3
• Start date: June 2016
• Est. completion date: October 2019

Study information

• Verified date: May 2020
• Source: Jiangsu Province Centers for Disease Control and Prevention
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In order to evaluate immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine produced by Beijing Minhai Biotechnology Co., Ltd., a randomized, double-blind, parallel-controlled phase III clinical trial is planned to conduct in healthy infants aged 2 months in China.

Description:

There will be two arms. 1200 healthy infants aged 2 months will be randomly assigned (1:1) to receive an experimental vaccine or a comparator vaccine in Month 0,2 and 4 (primary vaccination). All of them will receive a fourth dose as booster vaccination in Month 10.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1200
• Est. completion date: October 2019
• Est. primary completion date: December 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 42 Days to 77 Days

Eligibility

Inclusion Criteria:

• Aged 42-77 days old on the day of inclusion

• Subjects' legal guardians are able to understand and sign the informed consent

• Subjects' legal guardians can and will comply with the requirements of the protocol

• Subjects with temperature <=37.0°C on axillary setting

Exclusion Criteria for First Vaccination:

• Preterm infants or low birth weight infants

• Any administration history of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine

• A medical history of culture-confirmed invasive disease caused by Streptococcus pneumonia

• Subject who has allergic history or serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain

• Subject with congenital malformation, developmental disorder, genetic defects or severe malnutrition

• Subject with epilepsy, a history of seizures or convulsions, or a family history of mental illness

• Known or suspected immune deficiency or immune suppression

• Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder

• Had immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (not including allergic rhinitis corticosteroid spray treatment, acute uncomplicated dermatitis surfaces corticosteroid therapy) in the past 6 months

• Any prior administration of blood products in last 3 months

• Any prior administration of any attenuated live vaccine in last 14 days

• Any prior administration of subunit or inactivated vaccines in last 7 days

• Any acute infection or serious infection needing systemic antibiotics or antiviral treatment in last 7 days

• Any fever with temperature >=38.0°C on axillary setting in last 3 days

• Any other factors judged by investigator, that may interfere subject's compliance with the protocol

Exclusion Criteria for Second/Third and Booster Vaccination:

If one of the following (1) to (3) adverse events (AE) occurs, further vaccination is prohibited, but other study steps can be continued according to the judgment of the investigators; If one of the following (4) to (5) adverse events occurs, the investigator shall determine whether to continue the following vaccination. In the event of one of the following adverse events (6) to (7), vaccination may be postponed within the time window specified in the protocol.

• (1)The subjects have suffered from severe adverse events caused by the previous vaccination.

• (2)The subjects suffered from severe allergic reactions or hypersensitivity after the previous vaccination.

• (3)Known or suspected autoimmune diseases or immunodeficiency diseases,including HIV infection.

• (4)The occurrence of acute or emerging chronic diseases at the time of vaccination.

• (5)Other reactions (including severe pain, severe swelling, severe restriction of movement, persistent high fever, severe headache, or other systemic or local reactions) judged by the investigators.

• (6)Acute illness (acute illness refers to moderate or severe illness with or without fever) at the time of vaccination.

• (7)The axillary temperature >37.0? at the time of vaccination.

Related Conditions & MeSH terms

• Pneumonia

Intervention

Biological:
• 13-valent pneumococcal conjugate vaccine
0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
• Prevnar 13
0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose

Locations

Country	Name	City	State
China	Hongze District Center for Disease Control and Prevention	Huai'an	Jiangsu
China	Huaiyin District Center for Diseases Control and Prevention	Huai'an	Jiangsu
China	Lianshui County Center for Disease Control and Prevention	Huai'an	Jiangsu
China	Guanyun County Center for Disease Control and Prevention	Lianyungang	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Jiangsu Province Centers for Disease Control and Prevention	Beijing Minhai Biotechnology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 0.35 ug/mL 30 days after primary vaccination	Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 0.35 ug/mL 30 days after primary vaccination	30 days after primary vaccination
Primary	Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination	Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination	30 days after primary vaccination
Secondary	Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 1.0 ug/mL 30 days after primary vaccination	Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 1.0 ug/mL 30 days after primary vaccination	30 days after primary vaccination
Secondary	Geometric mean fold increase (GMI) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination	Geometric mean fold increase (GMI) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination	30 days after primary vaccination
Secondary	Proportion of subjects with serotype-specific geometric mean titer measured by OPA =1:8 30 days after primary vaccination	Proportion of subjects with serotype-specific geometric mean titer measured by OPA =1:8 30 days after primary vaccination	30 days after primary vaccination
Secondary	Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after primary vaccination	Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after primary vaccination	30 days after primary vaccination
Secondary	Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 0.35 ug/mL 30 days after booster vaccination	Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 0.35 ug/mL 30 days after booster vaccination	30 days after booster vaccination
Secondary	Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 1.0 ug/mL 30 days after booster vaccination	Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 1.0 ug/mL 30 days after booster vaccination	30 days after booster vaccination
Secondary	Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after booster vaccination	Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after booster vaccination	30 days after booster vaccination
Secondary	Proportion of subjects with serotype-specific geometric mean titer measured by OPA =1:8 30 days after booster vaccination	Proportion of subjects with serotype-specific geometric mean titer measured by OPA =1:8 30 days after booster vaccination	30 days after booster vaccination
Secondary	Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after booster vaccination	Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after booster vaccination	30 days after booster vaccination
Secondary	Incidence of adverse reactions (including systemic and local adverse reaction) 30 days after each dose of vaccination	Incidence of adverse reactions (including systemic and local adverse reaction) 30 days after each dose of vaccination	30 days after each dose of vaccination
Secondary	Incidence of severe adverse event (SAE) within 6 months after the first doseof vaccination	Incidence of severe adverse event (SAE) within 6 months after the first doseof vaccination	6 months after the first doseof vaccination
Secondary	Incidence of severe adverse event (SAE) 30 days after booster vaccination	Incidence of severe adverse event (SAE) 30 days after booster vaccination	30 days after booster vaccination